Owning this stock keeps me humble. By my measure immune therapy and its CCR5 nexus is literally everywhere in medical science. There is a virtual flanking movement going on in the world of science when it comes to this subject.This paper and its CCR5 subject matter will be presented April 8 at the AACR meeting. Yet, I and a few others who own a stock preeminently situated in this field of medical science and it is valued at l7cents. So I wonder? Am I a thwarted captain of industry or a mini Ahab?